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ABSTRACT
DNA topoisomerase (topo) II modulates DNA
topology and is essential for cell division. There are
two isoforms of topo II (a and b) that have limited
functional redundancy, although their catalytic
mechanisms appear the same. Using their COOH-
terminal domains (CTDs) in yeast two-hybrid
analysis, we have identified phospholipid scram-
blase1(PLSCR1)asabindingpartnerofbothtopoIIa
and b. Although predominantly a plasma membrane
protein involved in phosphatidylserine externaliza-
tion, PLSCR1 can also be imported into the nucleus
where itmayhave a tumour suppressorfunction. The
interactions of PLSCR1 and topo II were confirmed
by pull-down assays with topo II a and b CTD
fusion proteins and endogenous PLSCR1, and by
co-immunoprecipitationofendogenousPLSCR1and
topo II a and b from HeLa cell nuclear extracts.
PLSCR1 also increased the decatenation activity of
human topo IIa. A conserved basic sequence in the
CTD of topo IIa was identified as being essential for
binding to PLSCR1 and binding of the two proteins
could be inhibited by a synthetic peptide corre-
sponding to topo IIa amino acids 1430-1441. These
studies reveal for the first time a physical and
functional interaction between topo II and PLSCR1.
INTRODUCTION
The a and b isoforms of mammalian DNA topoisomerase
II (topo II) decatenate double-stranded DNA and are
involved in numerous cellular processes including replica-
tion, gene transcription, chromosomal segregation, diﬀer-
entiation and apoptosis as well as playing an important
role in chromatin structure and remodelling (1). Topo IIa
is found mainly in proliferating cells and its expression
levels vary substantially in diﬀerent phases of the cell cycle
(2). In contrast, topo IIb is expressed at constant levels
throughout the cell cycle and in a broad range of cell
types, with higher expression levels during embryogenesis
and in tumour cells (2,3). Topo IIb has also been impli-
cated in cellular maturation and diﬀerentiation in the
brain (4,5). The two mammalian isoforms have compar-
able catalytic activities in that both can complement
functional defects in yeast that conditionally lack the
single yeast topo II isoform (6). However, Top2a-/- mice
die early in embryogenesis because nuclei fail to divide
properly (7), while Top2b-/- mice die at birth due to
defects in diaphragm muscle innervation and have
signiﬁcant abnormalities in neurogenesis (8,9). Thus,
topo IIa is essential for cell division, while topo IIb
serves a critical role in development.
In addition to their roles in cellular proliferation and
diﬀerentiation, topo II a and b are well-established targets
in cancer chemotherapy (10–12). Clinically important and
widely used topo II-targetting drugs such as doxorubicin
and etoposide are considered topo II poisons because they
stabilize cleaved DNA/enzyme complexes, leading to the
induction of apoptosis (10,11). Other drugs are known as
catalytic inhibitors and act at diﬀerent stages of the topo
II catalytic cycle, such as when topo II binds to DNA
or ATP (12). There is a substantial body of compelling
evidence indicating that changes in topo II expression,
function and/or localization can play a major role in the
response of cancer cells to drugs that target these enzymes
(13–17).
Both topo II a and b consist of three domains: the
NH2-proximal ATPase domain, the central DNA cleavage
and religation domain (both of which are highly
conserved), and the divergent COOH-terminal domains
(CTDs) (18). Mutant topo IIa lacking its CTD retains
activity in vitro, indicating that the CTD has more of
a regulatory function rather than being essential for
catalytic activity (19,20). The CTDs of topo II contain
most of the utilized phosphorylation sites which are
COOH-proximal to the enzymes’ nuclear export
sequences (NES) (21–24). The CTDs also contain
nuclear localization sequences (NLS) (24) and mutations
in these sequences (at least in topo IIa) lead to
cytosolic localization of the protein and confer drug
resistance (13,14,16,17). Quite recently, Linka et al. (25)
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important determinants of the isoform-speciﬁc functions
of these enzymes.
Previous studies have shown that human topo IIa and
topo IIb both participate in protein–protein interactions
with a diverse range of nuclear proteins, including p53
(26), retinoblastoma protein (27), cyclic AMP-response
element-binding protein and c-Jun (28), histone deacety-
lase (HDAC) 1 and 2 (29,30), 14-3-3e (31) and caspase-
activated DNase (CAD) nuclease (32,33). However, there
is evidence that the screens for topo II protein binding
partners to date have been incomplete. In the present
study, by using yeast two-hybrid analysis with the CTDs
of topo II a and b as ‘bait’, we have identiﬁed phos-
pholipid scramblase 1 (PLSCR1) as a novel binding
partner of both isozymes. While the majority of studies of
this primarily plasma membrane localized protein have
focused on its role in phosphatidylserine externalization
during apoptosis, PLSCR1 is also actively imported into
the nucleus, where it appears to have a role in cellular
proliferation and diﬀerentiation (34,35). Since topo II is
involved in proliferation (a isoform) and diﬀerentiation
(b isoform), and both isoforms are known to have a role
in the cellular responses to cytotoxic drugs, our ﬁndings
raise the intriguing possibility that interactions between
topo II and PLSCR1 may inﬂuence tumour cell growth
and drug responsiveness.
MATERIALS AND METHODS
Plasmid construction
‘Bait’ plasmids pOBD2/topo IIa1152-1531 and pOBD2/
topo IIb1165-1621 were prepared by PCR ampliﬁcation of
pBS/hTOP2 (ATCC, Rockville, MD) and pYEShTOP2B
(gift of Dr. I. Hickson, Oxford, UK), respectively, using
PfuTurbo DNA polymerase (Stratagene, LaJolla, CA,
USA) and oligonucleotide primers to create Nco1 and
Xma1 sites at the 50 and 30 ends of the PCR products,
respectively. The PCR products were cloned into Nco1/
Xma1 digested pOBD2. pACT2/HDAC1220-482 was
supplied by Dr. B. Turner (University of Birmingham,
UK) (30).
pGEX6P-1/topo IIaCTD (containing amino acids
1171-1531) and pGEX6P-1/topo IIbCTD (containing
amino acids 1184-1621) were prepared by PCR ampliﬁca-
tion of pBS/hTOP2A and pYEShTOP2B, respectively,
to add SmaI and XhoI restriction sites in the correct
reading frame at the 50 and 30 ends, respectively, and to
add two glycine residues as a ﬂexible spacer between
glutathione S-transferase (GST) and the topo II fragment.
These PCR fragments were cloned in-frame at the 30 end
of GST using the SmaI and XhoI sites of pGEX-6P-1
(Amersham Biosciences, Baie D’Urfe ´ , QC, Canada).
pGEX6P-1/topo IIa1258-1531 and pGEX6P-1/topo
IIa1365-1531 were prepared by digesting pGEX6P-1/
topo IIaCTD with Sma1/Stu1 and Sma1/SnaB1, respec-
tively, and re-ligating the plasmid backbone to itself.
Site-directed mutagenesis, as described subsequently, was
then used to create the SnaB1 site and appropriate stop
codons in pGEX6P-1/topo IIa1171-1531, thus generating
pGEX6P-1/topo IIa1171-1431, pGEX6P-1/topo IIa1171-
1441, pGEX6P-1/topo IIa1171-1461 and pGEX6P-1/topo
IIa1171-1477.
pMAL-C2/PLSCR1 was prepared by PCR ampli-
ﬁcation of pCMV-SPORT6.1/PLSCR1 (ATCC) using
Platinum Pfx polymerase (Gibco-BRL) and primers to
create a PCR product with 50 EcoRV and 30 EcoR1 sites.
The PCR fragment was cloned into Xmn1/EcoR1 digested
pMAL-C2. All restriction enzymes and pMAL-C2 were
from New England Biolabs (Ipswich, MA, USA), primers
were from IDT (Coralville, IA, USA), and the ﬁdelity
of the constructs was conﬁrmed by sequencing.
Site-directed mutagenesis
Site-directed mutagenesis was performed using PfuTurbo
DNA polymerase and mutagenic forward and reverse
complementary primers to amplify pGEX6P-1/topo
IIaCTD containing the desired mutations. In all cases,
mutations were conﬁrmed by sequencing prior to sub-
cloning appropriate fragments into parental vectors.
The SnaB1 site in pGEX6P-1/topo IIaCTD was created
using a primer with the sequence 50-CCCCAAAACTT
ACGTACAAAGAACTGAAACC-30 and its complement
(new SnaB1 site italicized). The new stop codons in
pGEX-6P-1/topo IIa CTD, which created pGEX6P-1/
topo IIa 1171-1431, 1171-1441, 1171-1451, 1171-1461 and
1171-1477, were generated using the following primers and
their complements (newly introduced Xma1 sites are
italicized and inserted stop codons are in boldface):
50-CC ACT ACC GGT TAG AAC CCG GGG GCT
GCC CCA AAA G-30,5 0-CCA AAA GGA ACT TAA
AGC CCG GGA GCT TTG AAT TCT GG-30,5 0-G AAT
TCTGGTGTCTAACACCCGGGTGATCCTGCC-30,
50-CC AAA ACC AAG TAG CGC CCG GGA AGG AAG
CCA TCC-30 and 50-CT GAC TCT AAT TAG GAC CCG
GGT GTT TCG AAA GC-3’.
Yeasttwo-hybrid analysis
Two-hybrid screening was performed using yeast strain
PJ69-4A (ATCC 201540). Yeast harbouring a bait
plasmid (pOBD2/topo IIa1152-1531 or pOBD2/topo
IIb1165-1621) were transformed with a human B lympho-
cyte library (ATCC 87003) (provided by Dr. D. LeBrun,
Queen’s University), and HIS3 and ADE2 reporter gene
expression monitored on histidine and adenine deﬁcient
agar plates (interaction-selective plates). Plasmids were
isolated, transformed into JF1754, and then grown on
leucine-deﬁcient agar plates. Plasmids isolated from
JF1754 colonies were transformed into PJ69 harbouring
pOBD2/topo IIa1152-1531 or pOBD2/topo IIb1165-1621
to conﬁrm interactions, or into PJ69 harbouring pOBD2
to identify false positives. Plasmids that encoded putative
topo II a or b interacting proteins were sequenced and the
partner proteins identiﬁed by comparison to nucleotide
databases.
Purification of GSTand MBP fusionproteins
BL21(DE3)-RIL Escherichia coli cells (Stratagene) trans-
fected with the pGEX6P-1/topo IIa or pMAL-C2/
PLSCR1 constructs were used to express GST-topo IIa
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proteins, respectively. Bacteria were induced with
1.0mM isopropyl-1-thio-b-D-galactopyranoside (IPTG)
for 3h, harvested and then sonicated in PBS containing
a protease inhibitor cocktail (Roche, Laval, QC, Canada),
DTT (5mM) and benzamidine (10mg/ml). Lysates con-
taining GST-topo IIa fusion proteins were pre-cleared by
ultra-centrifugation and batch-bound overnight to
GSH-Sepharose 4B (Amersham Biosciences, Uppsala,
Sweden). GST-topo IIa fusion proteins were eluted with
50mM Tris pH 7.5 containing 15mM GSH, 5mM DTT
and a protease inhibitor cocktail, and dialysed overnight
against PBS. Lysates containing the MBP-PLSCR1 fusion
protein was treated in a similar manner, except that it was
bound to amylose resin (New England Biolabs), eluted
with PBS containing 10mM maltose, 5mM DTT and a
protease inhibitor cocktail, and dialysed against PBS
containing 250mM sucrose. Puriﬁed fusion proteins were
stored at  808C.
Immunoblotting
Protein samples were resolved by Tricine gel electro-
phoresis (binding assays involving recombinant
PLSCR1) or SDS-PAGE (all other samples) and trans-
ferred to polyvinylidene ﬂuoride membranes in 50mM
N-cyclohexyl-3-aminopropanesulfonic acid, pH 11 (for
topo II immunoblots) or carbonate buﬀer pH 9.0
containing 20% methanol (for all other immunoblots).
Membranes were incubated with primary antibodies
overnight at 48C in TBS-T (50mM Tris-HCl pH 7.4,
150mM NaCl, 0.1% Tween-20) containing 4% (w/v) skim
milk powder. The ﬁlters were washed in TBS-T, incubated
for 1h with the appropriate horseradish peroxidase
conjugated anti-mouse or anti-rabbit secondary antibody,
and then developed using chemiluminescence detection
(Amersham Pharmacia Biotech).
Topo II a and b speciﬁc mAbs, 8D2 and 3H10,
respectively, were supplied by Dr A. Kikuchi (Nagoya
University, Japan) (36). A PLSCR1-speciﬁc polyclonal
antiserum generated against the 14 COOH-terminal
amino acids of PLSCR1 (CESTGSQEQKSGVW) was
supplied by Dr D. Bratton (National Jewish Medical and
Research Center, Denver, CO) (37). A mAb against
tubulin and a polyclonal antibody against calnexin were
from Sigma Diagnostics; a mAb against lysosomal-
associated membrane protein (LAMP) 2 was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Co-immunoprecipitation of topoII and PLSCR1
HeLa cell nuclear extracts were prepared by lysing
approximately 100 10
6 cells in hypotonic buﬀer
(10mM HEPES pH 7.6, 15mM KCl, 2mM EDTA,
0.5mM spermidine, 0.5mM spermine, 0.5% NP-40) on ice
for 15min, underlaying the suspension with a 30% sucrose
solution in the same buﬀer and centrifuging at 2200 g
for 20min. The pellet was resuspended in nuclear lysis
buﬀer (10mM HEPES, 100mM KCl, 0.1mM EDTA,
10% glycerol, 3mM MgCl2), and KCl added to a ﬁnal
concentration of 0.55M. After incubation for 30min,
the nuclear lysate was centrifuged at 100000 g and the
supernatant dialysed overnight against 50mM Tris
(pH 7.5)/150mM NaCl. The dialysate was centrifuged at
15000 g prior to overnight incubation with antibodies
against topo IIa (mAb 8D2), topo IIb (mAb 3H10),
PLSCR1, or pre-immune serum at 48C. Gamma-Bind
Sepharose
TM (Amersham) was then added for 1h prior
to collecting the beads by centrifugation. Bound proteins
were eluted with sample buﬀer and analysed by immuno-
blotting with topo II a and b mAbs 8D2 and 3H10 as
described above.
Confocal microscopy
HeLa cells were grown on gelatin-coated glass coverslips
until approximately 80% conﬂuent, ﬁxed in 3.7%
formaldehyde and then permeabilized in 1% TX-100.
After blocking for 1h in 1% BSA, cells were incubated
with topo II a or b mAbs and PLSCR1 antiserum (ICN,
Aurora, OH, USA). Antibody binding was detected with
Alexa546
TM goat anti-mouse and Alexa488
TM goat anti-
rabbit conjugated secondary antibodies (Molecular
Probes, Eugene, OR, USA) and ﬂuorescent images were
captured using a Leica TCS SP2 multiphoton confocal
microscope.
GST-pull-down assays
GST-pull-down assays of GST-tagged topo II CTD
fusion proteins and endogenous PLSCR1 were per-
formed using NP-40 lysates prepared from HeLa cells.
Cells were lysed in 50mM Tris-HCl (pH 7.5), 150mM
NaCl, protease inhibitors and 0.5% NP-40 (lysis buﬀer)
for 15min on ice. The lysate was cleared by centrifuga-
tion and the resulting supernatant incubated with
puriﬁed GST or GST-topo II CTD fusion proteins for
90min at 208C. In some cases, the lysate was treated with
40mU/ml Turbo
TM DNase 1 (Ambion, Austin, TX,
USA) for 60min at 208C prior to the addition of GST or
GST-topo II CTD fusion proteins. In some experiments,
recombinant PLSCR1 was used in place of HeLa cell
lysates. For these studies, the MBP tag was ﬁrst removed
by digesting the recombinant protein with Factor Xa and
incubating with X-Arrest agarose (Novagen, San Diego,
CA, USA). GSH-Sepharose 4B was then added and after
1h, the beads were collected by centrifugation. Bound
proteins were eluted with sample buﬀer and analysed by
immunoblotting using PLSCR1 antiserum as described
earlier.
Decatenation assay
To measure the eﬀect of PLSCR1 on topo II activity,
recombinant MBP-PLSCR1 was digested with Factor
Xa as above and  2pmol PLSCR1 was incubated with
0.4 U puriﬁed human topo IIa for 1.5h at 208C according
to the manufacturer’s instructions (TopoGEN, Inc., Port
Orange, FL, USA). The protein mixture was then
incubated with kinetoplast DNA (kDNA) for 15min
at 378C. After terminating the reactions, the samples
were resolved on a 1% agarose gel containing ethidium
bromide.
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Dodecapeptides corresponding to residues 1430-1441 of
topo IIa (TGAKKRAAPKGT) or the same amino acids
in random order (KRGATAKGTAPK) were purchased
from Bio-Synthesis (Lewisville, TX, USA). After remov-
ing the MBP tag with Factor Xa, recombinant PLSCR1
was incubated with increasing concentrations of peptide
for 1h at 208C. Puriﬁed GST or GST-topo IIa1258-1531
was then added and samples were treated as described
earlier for the GST- pull-down assay.
RESULTS
IdentificationofPLSCR1asatopoIIaandbbindingpartner
Vectors encoding the topo II CTDs expressed as NH2-
terminal fusion proteins with the DNA binding domain of
the GAL4 transcription factor (pOBD2/topo IIa1152-
1531 and pOBD2/topo IIb1165-1621) were constructed,
and expression in Saccharomyces cerevisiae yeast strain
PJ69 was conﬁrmed by immunoblotting (data not shown).
While the GAL4-topo IIb construct was expressed as
a single protein, several degradation products of the
polypeptide encoded by the topo IIa construct were seen,
suggesting that the product of this construct might be
unstable or toxic to yeast. This may be a general problem
in yeast two-hybrid screens using human topo IIa as bait,
since a screen of a HeLa cell library for topo IIb binding
partners was successful (38), as were two screens for yeast
topo II (39,40), while no yeast two-hybrid screens for topo
IIa binding partners have been reported.
No growth was detected on interaction-selective plates
when either pOBD2/topo IIa1152-1531 or pOBD2/topo
IIb1165-1621 were co-transformed with pACT/SNF4
(negative control) while growth was detected when
co-transformed with pACT/HDAC220-482 (positive con-
trol) (29,30), suggesting the two topo II constructs
were suitable candidates for yeast two-hybrid analysis
(Table 1). Screening of the library, identiﬁed several clones
as potential binding partners of both the topo II a and b
CTDs, one of which was conﬁrmed by sequencing as
PLSCR1. Human PLSCR1 has 318 amino acids and
the clone obtained, pACT/PLSCR1, encoded a polypep-
tide missing amino acids 1-29 and 118-143. Yeast
co-transformed with pACT/PLSCR1 and pOBD2 failed
to grow on selective plates, demonstrating that transcrip-
tion was not induced by pACT/PLSCR1 independently of
its interaction with the topo II CTDs.
Confirmation of interactions between PLSCR1 and topo IIa
and binvitro
To conﬁrm the interactions of topo IIa and topo IIb with
PLSCR1, the binding of endogenous PLSCR1 to GST-
tagged topo IIa CTD and topo IIb CTD fusion proteins
was investigated using HeLa cell lysates. To eliminate the
possibility that the interactions between PLSCR1 and the
topo II fragments were DNA-mediated, the cell lysates
were pre-treated with DNase1. However, as shown in
Figure 1, addition of DNase1 had no eﬀect on the binding
between either of the topo II CTD fusion proteins and
endogenous PLSCR1, indicating that the interactions are
DNA independent. The input lane in the immunoblot
shown represents 5% of the lysate used in the binding
assay, suggesting that the interactions may be relatively
weak, at least under the conditions of this assay, although
other explanations are possible.
Of some interest, the addition of a FLAG tag to the
NH2-terminus of PLSCR1 completely inhibited the inter-
action of the protein with the GST-tagged topo IIa CTD
(results not shown). The reason for this is unknown but
may be related to the highly charged nature of the FLAG-
tag, since the fusion of MBP to the NH2-terminus of
PLSCR1 did not aﬀect its binding to either of the GST-
topo II a or b CTD fusion proteins (data not shown).
PLSCR1 co-fractionates with topoIIa andb
To conﬁrm that PLSCR1 colocalizes with topo II a and b
in intact cells, HeLa cell nuclei were isolated and the
relative amounts of nuclear and NP-40 soluble PLSCR1
and topo II a and b in the two cellular fractions were
determined by immunoblotting. Samples were prepared
from equivalent numbers of cells rather than equal protein
concentrations so that the relative fraction of total cellular
PLSCR1 present in the nucleus could be determined.
As shown in Figure 2A, the nuclear fraction contains
Table 1. Identiﬁcation of PLSCR1 as a binding partner of the topo II a
and b CTDs using yeast two-hybrid analysis
Plasmid combination Growth
a
pOBD2/topo IIa1152-1531+pACT/SNF4 –
pOBD2/topo IIb1165-1621+pACT/SNF4 –
pOBD2+pACT/PLSCR1 –
pOBD2/topo IIa1152-1531+pACT/PLSCR1 +
pOBD2/topo IIb1165-1621+pACT/PLSCR1 +
pOBD2/topo IIa1152-1531+pACT/HDAC1220-482  /+
pOBD2/topo IIb1165-1621+pACT/HDAC1220-482 +
aYeast strain PJ69 was co-transformed with the plasmids as indicated
and allowed to grow on interaction-selective plates. Growth was scored
by presence of colonies after 5 days at 308C. +, yeast growth;  ,n o
growth.
35 kDa endog
PLSCR1
input input GST GST
topo
IIβ
topo
IIα
topo
IIβ
topo
IIα
− DNase + DNase
Figure 1. GST-tagged topo IIa CTD and topo IIb CTD interact
with PLSCR1. An NP-40 soluble HeLa cell lysate (150mg protein)
was incubated sequentially with DNase1 (20 U), GST-tagged topo IIa
or topo IIb CTD fusion proteins (5mg) and GSH-Sepharose beads
(25 ml of 50% slurry) as described in Materials and Methods section.
The beads were collected by centrifugation and bound proteins
analysed by immunoblotting with rabbit PLSCR1 antiserum. Input
lane represents 5% of lysate used in binding assay.
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the NP-40 soluble fraction, an estimate that is supported
by confocal microscopy (see subsequently). The identity
of the 70kDa band is unknown, but it was consistently
present, albeit at variable levels. It was not detected by the
pre-immune serum and may be an undissociated dimer.
Topo II a and b were detected only in the nuclear fraction
as expected. A lack of ER and cytoplasmic contamination
of the nuclear lysates was demonstrated by immunoblot-
ting for calnexin (integral ER membrane marker), tubulin
(cytoskeletal marker) and LAMP2 (lysosomal marker)
(Figure 2B).
Endogenous topoIIa andbco-immunoprecipitate with
PLSCR1
To conﬁrm that endogenous topo II a and b interact
with endogenous PLSCR1 in intact cells, nuclear lysates
were subjected to immunoprecipitation analysis using a
PLSCR1 antiserum, followed by immunoblotting with
topo II a and b speciﬁc mAbs. As shown in Figure 3, both
topo II a and b were immunoprecipitated by the PLSCR1
antiserum, but not the pre-immune serum, demonstrating
that the endogenous proteins interact in vivo. These results
also show that the interaction is not an artifact caused
by the use of recombinant topo II CTDs rather than the
endogenous proteins, or the forced colocalization of pro-
teins that do not normally share a compartment, as can
occur in yeast two-hybrid analysis. The input lane repre-
sents 5% of the nuclear lysate used in each binding assay,
suggesting that as much as 5% of nuclear topo II a and b
is associated with PLSCR1. A high background associated
with the PLSCR1 antiserum in co-immunoprecipitation
experiments precluded consistent western blot detection of
nuclear PLSCR1 immunoprecipitated by the topo II a and
b speciﬁc mAbs (data not shown).
Nuclear colocalization ofPLSCR1 and topoIIaby confocal
microscopy
The nuclear colocalization of PLSCR1 and topo IIa in
HeLa cells was conﬁrmed by immunocytochemistry
(Figure 4). We found that 1% TX-100 and incubation
at 378C was needed to permeabilize the nucleus suﬃciently
to detect nuclear PLSCR1. These conditions also sub-
stantially increased staining of nuclear topo IIa. This
PLSCR1 staining pattern is consistent with a previous
study of PLSCR1 in HeLa cells using a diﬀerent primary
antibody (41). It is noted that nuclear localization of
PLSCR1 and its induction by interferons can vary
dramatically according to cell type (34).
Both topo IIa and PLSCR1 were localized
throughout the nucleus although, as reported by other
A
B
Nuc NP-40
α-LAMP2
100
kDa Nuc NP-40
α -calnexin
90
kDa Nuc NP-40
α-tubulin
50
kDa
Nuc NP-40
35
70
kDa
α-PLSCR1
Nuc NP-40
170
kDa Nuc NP-40
180
kDa
α-topo IIβ α-topo IIα
Figure 2. PLSCR1 co-fractionates with topo II a and b.( A) Nuclear
and NP-40 soluble lysates were prepared from HeLa cells as described
in Materials and Methods section for co-immunoprecipitation and
GST-pull-down assays, respectively. Samples representing equivalent
numbers of cells were analysed by immunoblotting with antibodies
against PLSCR1, topo IIa (mAb 8D2) and topo IIb (mAb 3H10).
(B) The same samples described in Panel A were analysed for calnexin,
LAMP2 and tubulin content by immunoblotting to conﬁrm the absence
of contaminating ER, lysosomal and cytoskeletal proteins, respectively.
To prevent overexposure of the ﬁlm due to high intensity signals,
the analyses for tubulin and calnexin content used 10% of the number
of cells used for other immunoblots. Nuc, nuclear lysate; NP-40, NP-40
soluble lysate; TX-100, Triton X-100 soluble lysate.
IB: α-topo IIα
IB: α-topo IIβ
input
IP Ab
anti-
PLSCR1 pre-imm
Figure 3. Endogenous topo II a and b co-immunoprecipitate with
endogenous PLSCR1. Nuclear extracts prepared from HeLa cells were
subjected to co-immunoprecipitation with an anti-PLSCR1 antiserum
or pre-immune serum as described in Materials and Methods section.
Immunoprecipitated samples were then analysed by immunoblotting
with topo II a and b speciﬁc mAbs 8D2 and 3H10, respectively. Input
lanes represent 5% of sample used in the assay. Shown are results from
a representative experiment and similar results were obtained in two
additional experiments.
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nucleoli of some cells (Figure 4, Panels A and D). Not
unexpectedly, given the diﬀerences in the relative abun-
dance of the two proteins, the signal intensity for nuclear
PLSCR1 (Panel B) was very low compared to that for
topo IIa, making colocalization studies diﬃcult. However,
examination of the separate images showed a small
increase in PLSCR1 staining in the nucleoli relative to
the nucleoplasm. This was not caused by overlap of the
red channel (topo IIa) into the green channel (PLSCR1),
since cells treated with the pre-immune serum in place of
the PLSCR1 antiserum did not display an increased
green signal in the nucleoli (Panel E). Unfortunately,
comparable colocalization experiments of PLSCR1 and
topo IIb were unsuccessful since staining by the topo
IIb-speciﬁc mAb under the ﬁxation conditions required to
detect nuclear PLSCR1 was poor.
Recombinant PLSCR1 stimulates the decatenation activity
of topoIIa
The ability of PLSCR1 to modulate topo II activity was
assessed using a topo II assay that measures the
decatenating activity of the enzyme. Thus puriﬁed topo
IIa was preincubated with PLSCR1 for 1.5h at 208C prior
to incubation with kDNA for 15min at 378C. As shown in
Figure 5, the catenated kDNA did not enter the gel
(lane 5) as expected, while decatenated DNA entered the
gel, but its electrophoretic mobility was slightly retarded
compared to linear DNA (compare lanes 6 and 7).
The addition of recombinant PLSCR1 to the assay mix-
ture signiﬁcantly increased the ability of topo IIa to
decatenate kDNA (compare lanes 3 and 4 versus 1 and 2).
Topo IIaresidues 1432-1441are essential forbinding to
PLSCR1
To identify the region of topo IIa that mediates binding to
PLSCR1, eight GST fusion proteins encoding NH2– and
COOH– truncated forms of the topo IIa CTD (Figure 6A,
upper panel) were generated and tested for their ability
to bind endogenous PLSCR1 in a GST-pull-down assay.
Only one of these fusion proteins (topo IIa1171-1431)
failed to bind to endogenous PLSCR1, indicating that
topo IIa residues 1432-1441 are required for binding to
PLSCR1 (Figure 6A, lower panel).
To conﬁrm that these residues were required, a dodeca-
peptide corresponding to topo IIa amino acids 1430-1441
(TGAKKRAAPKGT) was examined for its ability to
inhibit the binding of GST-topo IIa1258-1531 to recom-
binant PLSCR1 in a GST-pull-down assay. A second
dodecapeptide consisting of the same amino acids in
random order was included as a negative control.
As shown in Figure 6B, the topo IIa peptide speciﬁcally
blocked the interaction between topo IIa and PLSCR1
in a concentration-dependent manner, while the random
peptide had no eﬀect. These observations provide further
conﬁrmation that residues 1432-1441 are involved in the
interaction of topo IIa with PLSCR1.
The CTDs of topo II a and b are poorly
conserved, making alignments of these regions diﬃcult.
D A
E
F
B
C
topo IIα
merged images
PLSCR1(B) or
pre-immune (E)
Figure 4. Colocalization of endogenous topo IIa and PLSCR1. HeLa
cells were cultured on gelatinized glass coverslips, ﬁxed in formaldehyde
and permeabilized with Triton X-100. Topo IIa was detected with
mAb 8D2 in conjunction with Alexa546
TM-conjugated goat anti-mouse
secondary antibody (Panels A and D, red signal) and PLSCR1 was
detected with rabbit PLSCR1 antiserum or the pre-immune serum
(Panels B and E, respectively, green signal) in conjunction with
Alexa488
TM-conjugated goat anti-rabbit secondary antibody. Merged
images are shown in Panels C (A+B) and F (D+E).
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Figure 5. PLSCR1 stimulates the decatenation activity of topo IIa.
Topo II decatenating activity was assayed using puriﬁed topo IIa
enzyme in the presence and absence of untagged recombinant PLSCR1
as described in Materials and Methods section. Similar results to those
shown were obtained in two additional experiments. The positions of
the catenated kDNA (cat kDNA), decatenated kDNA minicircles (dec)
and linear (lin) kDNA are indicated.
Nucleic Acids Research, 2007, Vol. 35, No. 12 4081Nevertheless, when residues 1424-1531 of topo IIa (exons
34-35) were aligned with residues 1493-1621 of topo IIb
(exons 34-36) (43), a basic stretch of seven amino acids
was identiﬁed between topo IIa residues 1433 and 1439
(topo IIb residues 1501-1507) (Figure 6C) that may form a
positively charged patch that mediates the interaction with
PLSCR1. These putative PLSCR1 interaction motifs are
both approximately the same distance from the COOH–
termini of their respective topo II isoforms and occur
within 9–10 residues of an intron/exon boundary (43).
Neither basic motif overlaps with previously identiﬁed
functional NLS or NES sequences (21,22,24) and both
are highly conserved in all vertebrate species for which
complete topo II sequences are available (human,
hamster, rat, mouse, chicken and pig).
DISCUSSION
Despite the established importance of the topo II isoforms
in cell division and as clinically important drug targets,
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Figure 6. Localization of PLSCR1 binding to amino acids 1432-1441 of topo IIa.( A) Upper panel, Schematic diagram showing the eight GST-
tagged topo IIaCTD fusion proteins used to deﬁne the region of topo IIa involved in binding to PLSCR1. Lower panel, NP-40 solubilized HeLa cell
lysates were incubated with each of the eight GST-topo IIaCTD fusion proteins and complexes pulled down with GSH-Sepharose beads as described
in Materials and Methods section. The proteins were eluted and immunoblotted with PLSCR1 antiserum. (B) Untagged recombinant PLSCR1 was
incubated with increasing concentrations of synthetic dodecapeptides corresponding to topo IIa residues 1430-1441 or as a control, randomly
scrambled topo IIa residues 1430-1441, and GST-topo IIa1258-1531 or GST alone (control). Complexes were pulled down with GSH-Sepharose
beads and bound proteins analysed by immunoblotting with PLSCR1 antiserum. The experiment shown was repeated three or more times with
comparable results. (C) The sequences of the COOH-termini of topo IIa and topo IIb were aligned using ClustalW. The basic conserved putative
PLSCR1 binding motifs in topo IIa and topo IIb are boxed; the vertical bars in the topo II sequences represent intron/exon boundaries (43), and the
functional NLS sequences in this region are underlined (topo IIa, solid line; topo IIb, broken line) (24).
4082 Nucleic Acids Research, 2007, Vol. 35, No. 12the cellular processes responsible for regulating their
function and activity are still not fully deﬁned. As the
identiﬁcation of protein–protein interactions can often
provide insight into regulatory pathways, we undertook
a search for novel topo II binding partners using yeast
two-hybrid analysis. The sequence divergent topo II CTDs
were used as bait because there is compelling evidence that
many of their regulatory elements are contained in this
region.
Since topo II a and b are normally localized to the
nucleus, we initially found it surprising that our analysis
identiﬁed PLSCR1, which is primarily localized to the
endofacial plasma membrane in most cell types, as a topo
II-binding protein. However, PLSCR1 can also be found
in the nucleus and other organelles, albeit at much lower
abundance (34,41). A non-classical functional NLS has
been identiﬁed in PLSCR1 (35,44) and it has been
demonstrated that PLSCR1 binds to a unique site in the
nuclear import carrier protein importin a (44). Thus, there
is strong evidence that under certain conditions, PLSCR1
is actively imported into the nucleus making its interaction
with topo II in vivo feasible.
PLSCR1at the plasma membrane is multiply palmitoy-
lated which, like other forms of lipid modiﬁcation, often
induces or enhances membrane localization (34,45). The
factors that regulate PLSCR1 palmitoylation are not
known, nor is it known precisely how palmitoylation
aﬀects the non-plasma membrane localization or function
of this protein. However, when palmitoylation of PLSCR1
is inhibited, either by mutation of the palmitoylated
cysteines in the COOH-proximal end of the protein or by
treatment of cells with 2-bromo-palmitate, PLSCR1
becomes primarily localized to the nucleus (34). Since
the conditions used to prepare samples for the topo II
pulldown and co-immunoprecipitation assays in the
present study would be expected to yield predominantly
palmitoylated and unpalmitoylated PLSCR1, respectively,
our observations suggest that palmitoylation does not
aﬀect the interaction of PLSCR1 with topo II a or b,
at least in vitro. However, because both topo II isoforms
are almost exclusively found in the nucleus, it would seem
likely that they interact primarily with unpalmitoylated
PLSCR1 in vivo.
Protein–protein interactions involving both yeast and
human topo II have been reported to result in several
diﬀerent functional consequences (26–33). In some cases,
the topo II–protein interactions modulate the DNA
decatenating activity of the enzyme which is critical for
regulated chromosomal segregation. Thus, HDAC1 and
the underphosphorylated form of the retinoblastoma
protein inhibit the DNA decatenating activity of human
topo IIa (27,29) while in contrast, the cyclic AMP-
response element-binding protein (28), the mitotic cdc2
cyclin-dependent kinase (23) and CAD nuclease stimulate
this activity (32). Our data indicates that PLSCR1 behaves
like the latter proteins in its ability to stimulate DNA
decatenation by topo IIa.
To better understand the molecular basis of the
interaction between topo II and PLSCR1, we investigated
the region of topo IIa responsible for its binding to
PLSCR1. Using a series of nested truncated GST-fusion
proteins in pull-down assays, a basic stretch of amino
acids (residues 1432-1441) in topo IIa in a region of the
enzyme that is predicted to be unstructured was shown to
be critical. The importance of these amino acids was
conﬁrmed by demonstrating that a synthetic dodecapep-
tide corresponding to this sequence could inhibit binding
of topo II and PLSCR1. However, while topo IIa
residues1432-1441 are essential, it remains possible that
they are not suﬃcient by themselves to mediate the inter-
action between the two proteins. Other proteins reported
to bind to the topo II CTD include HDAC1 and HDAC2
(30) and p53 (26). It will be of interest to determine the
relationships, if any, among the diﬀerent topo II CTD
binding proteins (which now includes PLSCR1) with
respect to topo II functions (25).
Most studies of PLSCR1 have focused on its role in
phospholipid mixing at the plasma membrane. More
recently it has been suggested that PLSCR1 may have
a role in suppressing tumorigenesis. For example, when
human ovarian tumour cells stably transfected with
PLSCR1 were implanted into athymic mice, the resulting
tumours were much smaller and more diﬀerentiated than
those arising from untransfected cells (46). Additionally,
Huang et al. (47) showed that induction of PLSCR1
arrested proliferation of human myeloid leukemia cells
and stimulated their diﬀerentiation. Elevated PLSCR1
mRNA levels have also been reported to be a positive
prognostic factor in a clinical study of patients with acute
myelogenous leukaemia (48). In contrast, when trans-
planted into syngeneic or athymic mice, an NH2-truncated
form of murine Plscr1 (designated as TRA1) is leukemo-
genic (49). Ongoing studies are aimed at determining how
the tumour-suppressor eﬀects of PLSCR1 might be related
to its eﬀects on topo II activity.
The function(s) of nuclear PLSCR1 is presently not well
understood. Recently, a domain within the putative
NH2-proximal regulatory region of PLSCR1 was shown
to stimulate expression of inositol 1,4,5-triphosphate
receptor type 1 (IP3R1), a protein involved in regulating
Ca
2+ release from the endoplasmic reticulum, by binding
directly to its promoter (50). It may be that PLSCR1
participates with other nuclear proteins to regulate
expression of IP3R1 and possibly other genes by recruiting
topo II or alternatively, topo II recruits PLSCR1 to speci-
ﬁc regions of DNA in order to regulate topo II activity.
For the topo II-nuclear protein interactions characterized
thus far, it is the interacting protein partner that appears
to be recruited by topo II (23,32,51). For example, it
has been shown that chromatin remodelling occurs in
response to topo II-mediated recruitment of the mitotic
cdc2 cyclin-dependent kinase (51).
IP3R1 seems unlikely to be the only gene regulated by
PLSCR1 and indeed, PLSCR1 has been reported to bind
to promoter fragments from three other uncharacterized
genes (50). PLSCR1 did not induce transcription from
these promoter fragments in a luciferase reporter assay, an
observation that could be explained if PLSCR1 is acting
as a negative regulator of these genes or if a necessary
adaptor protein was not present in the cells used. It has
also been shown that nuclear levels of PLSCR1 can be
enhanced substantially by treatment of at least some cell
Nucleic Acids Research, 2007, Vol. 35, No. 12 4083types with both type I and II interferons (46,52). Whether
or not the ability of PLSCR1 to modulate topo II activity
is involved in the cellular activities of interferons,
however, remains to be determined.
In conclusion, our study shows for the ﬁrst time
a physical and functional interaction between topo II
and PLSCR1. Further investigation of the interactions
between these proteins is needed to better understand their
possible role in tumour proliferation, as well as cellular
diﬀerentiation and drug responsiveness.
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